HOOKIPA Pharma(HOOK) - 2024 Q3 - Quarterly Results

Exhibit 99.1 HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates Enrollment of 68 patients completed Phase 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC four months ahead of schedule SITC 2024 late-breaking poster highlights Phase 2 eseba-vec data updates for increased number of patients reflecting ORR and durability in line with prior data First patients dosed in Phase 2 investigator led study with MSKCC in new clinical setting as adjuvant therapy for head ...